Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma.

Trial Profile

Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2009

At a glance

  • Drugs Dexamethasone; Plitidepsin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2008 Results have been presented at the 50th Congress of the American Society of Hematology (ASH) according to a PharmaMar media release; results were also reported in the media release.
    • 28 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2005 Interim results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top